“We had an initial pilot with an over-the-counter product Nicotex and that has been successful. We have now set up a subsidiary and looking to launch full range of nutritional products in next 12-18 months,” he stated. Saxena said Cipla's future growth will largely be organic and added the company was not under any compulsion to do mega acquisitions. He added the company would continue with its strategy of developing joint venture partnerships with pharmaceutical firms in other countries.
ALSO READ: Cipla Q1 net more than doubles to Rs 651 cr
The respiratory product business remains the focus area for the company and it expects half of the growth to come from existing markets, while the US and Europe will be new growth areas. “We see immense growth opportunities in this business segment in India,” Saxena said. The company is also looking to grow its product portfolio, develop better delivery systems for patients and expand its nasal spray portfolio.
ALSO READ: Cipla heir apparent Kamil steps down
Earlier in the day, Cipla Chairman Y K Hamied told shareholders that the firm has become more active in the US. “We have de-risked business in certain markets and have successfully incorporated subsidiary in Sri Lanka and Morocco and integrated our business in Myanamar, Uganda and Yemen,” Hamied said.
Compared to other large Indian pharma companies Cipla only earns about eight per cent of its revenue from the US market.
Cipla has given a revenue guidance of 20 per cent for FY16 and expects profits to be in line with revenue growth. The company achieved a revenue growth of 11,000 crore the last financial year. Its net profit doubled to Rs 651 crore in the first quarter FY16 and revenue grew 43 per cent to Rs 3,777 crore.